Monday, 16 Sep 2019

You are here

ACP Gout Guidelines Reviewed and Critiqued by Rheumatologists

The American College of Physicians (ACP) has issued a series of recommendations on the diagnosis and treatment of gout. For instance, they advocate for the use of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine in acute gout.

The ACP clinical practice guideline for the management of acute and recurrent gout puts forth four recommendations:

  • Recommendation 1: ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout. (Grade: strong recommendation, high-quality evidence)
  • Recommendation 2: ACP recommends that clinicians use low-dose colchicine when using colchicine to treat acute gout. (Grade: strong recommendation, moderate-quality evidence). ACP recommends that if colchicine is used, it should be at a low dose, as lower doses of colchicine are as effective as higher doses but have fewer gastrointestinal adverse effects. 
  • Recommendation 3: ACP recommends against initiating long-term urate–lowering therapy in most patients after a first gout attack or in patients with infrequent attacks. (Grade: strong recommendation, moderate-quality evidence)
  • Recommendation 4: ACP recommends that clinicians discuss benefits, harms, costs, and individual preferences with patients before initiating urate–lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks. (Grade: strong recommendation, moderate-quality evidence)

Also published in the Annals of Internal Medicine are ACP guidelines on the diagnosis of gout, wherein the ACP recommends that physicians use synovial fluid analysis when clinical judgment indicates that diagnostic testing is necessary in those with possible gout (Citation source: http://buff.ly/2fvULt7).  The clinical practice guideline for the diagnosis of gout can be found here - http://buff.ly/2fvXRx3. 

In the same issue, Drs.Tuhina Neogi (Boston) and Ted Mikuls (Omaha) wrote an accompanying editorial of the ACP guidelines. While they agreed with the high strength of evidence favoring the use of colchicine, nonsteroidal anti-inflammatory drugs, and corticosteroids for gout flare management, they disagreed on the ACP view of treat-to-target. (Citation source: http://buff.ly/2fihAvg.)

The ACP categorized the treat-to-target strategy evidence as being "low" and Drs. Neogi and Mikuls found their assertion to be puzzling and countered that there is at least a moderate strength of evidence supporting monitoring of serum urate levels and using this as a guide to urate lowering therapy (ULT).  They respond by saying the treat-to-avoid-symptoms approach (suggested by the ACP) has not been tested either. 

The current ACP gout guidelines are based on 2 systematic evidence reviews sponsored by AHRQ and conducted by the RAND Corporation's Southern California Evidence-based Practice Center. Problematic is their non-endorsement of the 2012 ACR gout guidelines. 

Drs. Mikuls and Neogi write, "The ACP CGC finds it difficult when it cannot endorse a widely disseminated recommendation from a fellow professional society because of a lack of adequate supporting evidence. Yet, it believes that evidence must direct guideline recommendations. Specifying clinical options when evidence is lacking is the role of expert consensus panels or best-practice statements, but these documents must not masquerade as the type of evidence-based guidelines defined by the IOM. As we try to provide our patients with the best possible care, we must be clear about when the best clinical decision is defined by high-quality evidence and when it is suggested by consensus."

The ACP guidelines have drawn criticism from numerous rheumatologists (see citations below):

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.